Free Trial
NASDAQ:PTPI

Petros Pharmaceuticals (PTPI) Stock Price, News & Analysis

Petros Pharmaceuticals logo
$0.05 0.00 (-8.55%)
As of 02:28 PM Eastern

About Petros Pharmaceuticals Stock (NASDAQ:PTPI)

Key Stats

Today's Range
$0.05
$0.05
50-Day Range
$0.04
$0.29
52-Week Range
$0.04
$0.77
Volume
5.46 million shs
Average Volume
29.86 million shs
Market Capitalization
$2.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Petros Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
4th Percentile Overall Score

PTPI MarketRank™: 

Petros Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Petros Pharmaceuticals.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Petros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Petros Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Petros Pharmaceuticals has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Petros Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    14.90% of the float of Petros Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Petros Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Petros Pharmaceuticals has recently increased by 98.58%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Petros Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Petros Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.90% of the float of Petros Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Petros Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Petros Pharmaceuticals has recently increased by 98.58%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    7 people have searched for PTPI on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Petros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Petros Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.25% of the stock of Petros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 12.34% of the stock of Petros Pharmaceuticals is held by institutions.

  • Read more about Petros Pharmaceuticals' insider trading history.
Receive PTPI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Petros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PTPI Stock News Headlines

Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
Petros Pharmaceuticals prices 40M shares at 24c in public offering
Petros Pharmaceuticals files to sell units, no amount given
See More Headlines

PTPI Stock Analysis - Frequently Asked Questions

Petros Pharmaceuticals' stock was trading at $0.3939 on January 1st, 2025. Since then, PTPI shares have decreased by 87.3% and is now trading at $0.0499.
View the best growth stocks for 2025 here
.

Petros Pharmaceuticals's stock reverse split on the morning of Wednesday, November 30th 2022. The 1-10 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of PTPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Petros Pharmaceuticals investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT), Cricut (CRCT) and JPMorgan Chase & Co. (JPM).

Company Calendar

Today
4/23/2025
Next Earnings (Estimated)
5/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTPI
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,160,000.00
Pretax Margin
-117.50%

Debt

Sales & Book Value

Annual Sales
$5.11 million
Price / Cash Flow
N/A
Book Value
$4.04 per share
Price / Book
0.01

Miscellaneous

Free Float
9,932,000
Market Cap
$2.67 million
Optionable
Not Optionable
Beta
2.17
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:PTPI) was last updated on 4/23/2025 by MarketBeat.com Staff
From Our Partners